ORGS (Orgenesis) Net Margin %: -6,769.44% (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ORGS Orgenesis Inc ORGS
12 GF Score
Price $0.10
View Full Analysis

What is Orgenesis Net Margin %?

Orgenesis ORGS 12 Net Margin % is -6,769.44% as of Dec. 2024. GuruFocus rates ORGS with a GF Score™ of 12/100.

Net margin is calculated as Net Income divided by its Revenue. Orgenesis's Net Income for the three months ended in Dec. 2024 was $-20.38 Mil. Orgenesis's Revenue for the three months ended in Dec. 2024 was $0.30 Mil. Therefore, Orgenesis's net margin for the quarter that ended in Dec. 2024 was -6,769.44%.

The historical rank and industry rank for Orgenesis's Net Margin % or its related term are showing as below:


ORGS's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -78.86
* Ranked among companies with meaningful Net Margin % only.

Orgenesis  (OTCPK:ORGS) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Orgenesis Net Margin % Related Terms

Orgenesis Net Margin % Historical Data

* Premium members only.

The historical data trend for Orgenesis's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orgenesis Net Margin % Chart

Orgenesis Annual Data
Trend Nov15 Nov16 Nov17 Nov18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.51 -50.85 -41.33 -10,445.47 -4,653.62

Orgenesis Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4,013.94 -6,925.53 -3,619.51 -2,628.24 -6,769.44

ORGS vs ENDV, GBLX, OMGAQ: Net Margin % Comparison

For the Biotechnology subindustry, Orgenesis's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Orgenesis Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orgenesis's Net Margin % distribution charts can be found below:

* The bar in red indicates where Orgenesis's Net Margin % falls into.


ORGS
12GF Score
Orgenesis Inc ORGS
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orgenesis Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Orgenesis's Net Margin for the fiscal year that ended in Dec. 2024 is calculated as

Net Margin=Net Income (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-48.165/1.035
=-4,653.62 %

Orgenesis's Net Margin for the quarter that ended in Dec. 2024 is calculated as

Net Margin=Net Income (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-20.376/0.301
=-6,769.44 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -6,769.44% mean?
Orgenesis (ORGS) has a Net Margin % of -6,769.44% as of Dec. 2024. Net margin is the ratio of total net income to net sales. View historical data on Orgenesis and its competitors.
Is Orgenesis' Net Margin % too high?
Orgenesis' current Net Margin % is -6,769.44%. Overall, Orgenesis has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Orgenesis' Net Margin % compare to ENDV and GBLX?
Orgenesis' Net Margin % of -6,769.44% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Orgenesis and its competitors. Orgenesis's current Net Margin % is -6,769.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orgenesis stock overvalued right now?
Orgenesis (ORGS) has a current Net Margin % of -6,769.44%. The current Net Margin % is -6,769.44%. Orgenesis' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Orgenesis (ORGS), the current Net Margin % is -6,769.44% as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Orgenesis Business Description

Address 20271 Goldenrod Lane, Germantown, MD, USA, 20876
Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Octomera and Therapies. The company's therapies pipeline includes Immuno-Oncology, Viral Diseases, Metabolic & Autoimmune Diseases, Vascular & Musculoskeletal Diseases, and Kidney Disease.
12GF Score

Get the complete analysis for ORGS

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.10
Price